Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 4/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928579 | 0.98 | KDM4E (0.76) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL4045277 | 0.95 | KDM4E (0.81) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL6127192 | 0.90 | KDM4E (0.89) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL27189083 | 0.89 | GAA (0.65) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL3077089 | 0.88 | KDM4E (0.74) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL31169755 | 0.87 | KDM4E (0.72) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL18197872 | 0.84 | KDM4E (0.84) | KDM4EHDAC1GAAHDAC3NPC1 | |
| SCHEMBL18906066 | 0.83 | KDM4E (0.83) | KDM4EHDAC1GAAHDAC3NPC1 | |
| SCHEMBL29358739 | 0.83 | HDAC1 (1.00) | KDM4EHDAC1HDAC11HDAC8HDAC6 | |
| SCHEMBL13617092 | 0.83 | KDM4E (0.71) | KDM4EHDAC1HDAC11HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1533311-B1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1533311-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1244657-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-0946552-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-6686382-B2 | N-(ISOXAZOLYL)THIENYLSULFONAMIDES, N-(ISOXAZOLYL)FURYLSULFONAMIDES, N-(ISOXAZOLYL)PYRROLYLSULFONAMIDES AND N-(ISOXAZOLYL)PHENYLSULFONAMIDES; INHIBIT ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| EP-1342721-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-0828488-B1 | ISOTHIAZOLONES | WARNER LAMBERT CO (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6133270-A | Isothiazolones and pharmaceutical formulations | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6001863-A | USEFUL AS ANTIVIRAL, ANTIINFLAMMATORY AND ANTIATHEROSCLEROSIS AGENT; ADMINISTERING TO THE PATIENT IN NEED OF ZINC EJECTION FROM NUCLEOCAPSID PROTEIN | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0946552-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5889034-A | ANTIINFLAMMATORY AGENT; ANTIATHEROSCLEROSIS AGENT; VIRICIDES | WARNER-LAMBERT COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| WO-1998013366-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
| US-5733921-A | ANTIRETROVIRAL AGENTS; ANTIINFLAMMATORY AGENTS; ANTIATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0828488-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| US-5620997-A | VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIATHEROSCLEROTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996038144-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | KDM4E 2082/4885HDAC1 1570/4885HDAC11 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.